ANGIOSARCOMA
Clinical trials for ANGIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new ANGIOSARCOMA trials appear
Sign up with your email to follow new studies for ANGIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer vaccine trial for rare skin cancer halted before starting
⭐️ VACCINE ⭐️ TerminatedThis study was designed to test a new mRNA vaccine for a rare skin cancer called cutaneous angiosarcoma. The goal was to find the highest safe dose and check for side effects. However, the study was withdrawn before any patients were enrolled, so no results are available.
Matched conditions: ANGIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:53 UTC
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for rare cancer: experimental combo targets angiosarcoma
Disease control OngoingThis study tests a new drug combination (vusolimogene oderparepvec plus pembrolizumab) in 18 adults with advanced angiosarcoma, a rare cancer of blood vessels. Participants must have already tried immunotherapy without success. The goal is to see if the treatment is safe and can …
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for rare cancers? eribulin tested in angiosarcoma and EHE
Disease control OngoingThis study tested the drug eribulin in 13 people with two rare cancers that start in blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). Participants had advanced disease that had already been treated. The main goal was to see if eribulin could shrink tumors. …
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New immunotherapy combo shows promise in advanced cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs (botensilimab and balstilimab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 499 participants with various can…
Matched conditions: ANGIOSARCOMA
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 08, 2026 12:02 UTC